肿瘤坏死因子受体超家族成员 1A 多态性可能是预测头颈部癌症患者严重放射性口腔黏膜炎的指标和预后因素。

Polymorphism of TNFRSF1 A may act as a predictor of severe radiation-induced oral mucositis and a prognosis factor in patients with head and neck cancer.

机构信息

Department of Human Physiology, Medical University of Lublin, Poland.

出版信息

Oral Surg Oral Med Oral Pathol Oral Radiol. 2020 Sep;130(3):283-291.e2. doi: 10.1016/j.oooo.2020.05.010. Epub 2020 May 26.

DOI:10.1016/j.oooo.2020.05.010

PMID:32561252

Abstract

OBJECTIVE

The aim of this study was to evaluate the relationship between single nucleotide polymorphism (SNP) (-135 T>C) of TNFRSF1 A and the frequency of occurrence and severity of oral mucositis (OM) in patients with head and neck cancer (HNC) treated with radiotherapy (RT).

STUDY DESIGN

This retrospective, cohort study included 60 patients with HNC treated with intensity-modulated radiation therapy (IMRT). TNFRSF1 A SNP analysis (-135 T>C) was performed by using molecular probes (TaqMan, ThermoFisher Scientific, Waltham, MA) in DNA isolated from peripheral blood (QIAamp DNA MiniKit; Qiagen, Germantown, MD).

RESULTS

CC genotype was related to 4.5-fold higher risk of grade 2 OM after the second week of RT. Similarly, CC carriers had a significantly higher risk of severe (grade 3) OM after the fourth (6-fold) and fifth (7.5-fold) weeks of RT. The CC genotype of the TNFRSF1 A gene was significantly correlated with a higher risk of shorter overall survival (OS) (> 37 months follow-up period; hazard ratio [HR] = 2.78).

CONCLUSIONS

SNP (-135 T>C) of the TNFRSF1 A gene may act as a predictor of OM occurrence in patients with HNC treated with IMRT. The studied SNP may also serve as a prognostic factor in such cases.

摘要

目的

本研究旨在评估肿瘤坏死因子受体超家族成员 1A（TNFRSF1A）单核苷酸多态性（SNP）（-135 T>C）与接受放射治疗（RT）的头颈部癌症（HNC）患者口腔黏膜炎（OM）的发生频率和严重程度之间的关系。

研究设计

这是一项回顾性队列研究，纳入了 60 例接受调强放疗（IMRT）的 HNC 患者。通过使用来自外周血的 DNA （QIAamp DNA MiniKit；Qiagen，Germantown，MD）中的分子探针（TaqMan，ThermoFisher Scientific，Waltham，MA）对 TNFRSF1A SNP 分析（-135 T>C）。

结果

CC 基因型与 RT 后第二周 2 级 OM 的风险增加 4.5 倍相关。同样，CC 携带者在 RT 后第四（6 倍）和第五（7.5 倍）周发生严重（3 级）OM 的风险显著更高。TNFRSF1A 基因的 CC 基因型与较短的总生存（OS）风险增加显著相关（>37 个月随访期；风险比[HR] = 2.78）。